Trial Profile
A Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, 5-Period Crossover, Phase 1b Study To Evaluate The Effects Of Single Oral Administration of TAK-071 On Scopolamine-Induced Cognitive Impairment In Healthy Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs TAK 071 (Primary) ; Donepezil; Scopolamine
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Takeda
- 27 Mar 2018 Status changed from recruiting to discontinued due to indication change.
- 26 Jan 2018 Planned End Date changed from 13 Oct 2017 to 14 Dec 2018.
- 26 Jan 2018 Planned primary completion date changed from 13 Oct 2017 to 14 Dec 2018.